Published in
Elsevier, The Lancet Oncology, 11(22), p. 1541-1559, 2021
DOI: 10.1016/s1470-2045(21)00402-2
Links
Tools
Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study
Journal article published in 2021 by
Fred Saad,
Eleni Efstathiou,
Gerhardt Attard,
Thomas W. Flaig,
Fabio Franke,
Oscar B. Goodman,
Stéphane Oudard 
,
Thomas Steuber,
Hiroyoshi Suzuki,
Daphne Wu,
Kesav Yeruva,
Peter De Porre,
Sabine Brookman-May,
Susan Li,
Jinhui Li
and other authors.
,
Thomas Steuber,
Hiroyoshi Suzuki,
Daphne Wu,
Kesav Yeruva,
Peter De Porre,
Sabine Brookman-May,
Susan Li,
Jinhui Li
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 